Healthcare M&A in Australia

Australia’s healthcare sector has become one of the most compelling M&A markets in the Asia Pacific region — and increasingly, one of the most actively traded globally. A combination of demographic tailwinds, structural fragmentation, and sustained private equity interest has driven deal volumes across GP clinics, dental groups, allied health practices, aged care facilities, and veterinary networks. For healthcare business owners contemplating a sale, the buyer universe has never been deeper or more competitive.

Why Australian Healthcare M&A Is Among the World’s Most Active

Three structural forces make Australia’s healthcare sector uniquely attractive to acquirers.

Demographics. According to the Australian Institute of Health and Welfare, Australians aged 65 and over are projected to represent 22% of the population by 2042, up from 16% in 2020. This creates structural, non-cyclical volume growth across aged care, GP services, allied health, and specialist medicine — the kind of demand profile that financial buyers prize above all else.

Fragmentation. Unlike the United States, where healthcare consolidation has been underway for decades, Australia’s primary and allied health sectors remain dominated by independent owner-operators. The top five dental groups control less than 15% of the market. Most allied health practices are single-site owner-operated businesses. This fragmentation is the consolidation opportunity.

Medicare. Australia’s universal public health insurance system creates a revenue floor for most healthcare services. For private equity buyers, Medicare-funded businesses offer something rare: predictable, government-backed demand with built-in annual indexation. It is the defensive earnings profile that makes healthcare a core PE allocation globally.

The result is a buyer market that now includes domestic ASX-listed healthcare groups, US and European private equity funds, New Zealand and APAC regional acquirers, and global diagnostics and hospital groups — all competing for the same pool of independent Australian healthcare operators.

Active Sub-Sectors and Deal Activity

GP Clinics and Medical Practices

The GP clinic roll-up strategy accelerated materially after COVID-19, as the pandemic highlighted the vulnerability of single-site practices and the operational advantages of scale. PE-backed consolidators including Cornerstone Health, MedHealth, and several unlisted groups have been active acquirers, alongside listed platforms such as Healius.

Valuations for GP practices typically range from 4–7x EBITDA, with the upper end achievable for practices with multiple billing practitioners, strong enterprise value, diversified payer mix, and long-tenure associates. Medicare billing compliance is central to due diligence: any bulk-billing irregularities or inappropriate claiming can result in significant price adjustments.

Dental Groups

Dental is the most consolidated of Australia’s healthcare sub-sectors and commands the highest multiples for high-quality assets. Abano Healthcare, Pacific Smiles (acquired by Genesis Care consortium), 1300Smiles, and numerous private equity-backed platforms have built national footprints through acquisition.

Dental practices achieve 6–10x EBITDA in structured processes, driven by high patient loyalty, strong recurring revenue from hygiene and maintenance visits, and predictable capex requirements. The key value drivers are patient numbers per chair, associate retention, private fee mix versus public patients, and practice management system quality.

Allied Health

Physiotherapy, psychology, podiatry, occupational therapy, and speech pathology are among the fastest-growing M&A sub-sectors in Australia. The NDIS (National Disability Insurance Scheme) has created substantial new demand for allied health services, and several PE-backed platforms are building national networks through acquisitions.

Allied health practices trade at 5–8x EBITDA. Quality of earnings analysis focuses on NDIS versus private pay mix, key-person risk (where the owner-clinician is also the primary revenue generator), and the proportion of revenue from high-margin private fee-for-service versus lower-margin government-funded work.

Aged Care

Aged care M&A in Australia has been shaped by the fallout from the Royal Commission into Aged Care Quality and Safety, which delivered its final report in March 2021 and triggered sweeping regulatory reform. Operators who could not meet the new staffing ratios, food standards, and quality requirements have exited — creating significant distressed M&A activity as facilities changed hands at steep discounts to replacement cost.

Aged care facilities are valued on an EV per operational bed basis (A$100,000–A$250,000 per bed depending on location, room mix, and ACFI revenue) or 7–12x EBITDA where earnings are stable. Regulatory compliance status — particularly the Aged Care Quality and Safety Commission star rating — is the single most important value determinant.

Veterinary

The veterinary sector has attracted significant global PE attention, with networks such as VCA, National Veterinary Care, Greencross (acquired by TPG), and Apiam Animal Health building significant Australian footprints. Veterinary practices achieve 7–11x EBITDA for well-run multi-vet clinics, supported by high client loyalty, low price sensitivity among pet owners, and a post-COVID pet ownership surge.

Diagnostics and Pathology

Australia’s pathology and diagnostic imaging markets are dominated by three listed groups — Sonic Healthcare, Healius, and Capitol Health — but regional independent operators attract consistent trade buyer and PE interest. Diagnostics achieves 8–14x EBITDA, reflecting the sector’s defensive characteristics, high barriers to entry (equipment, accreditation, referral networks), and low revenue churn.

Who Is Buying Australian Healthcare Businesses

“Australian healthcare is one of the most internationally sought-after sectors globally,” says Daniel Bae, Managing Director of Lyndon Advisory and former M&A advisor with over US$30 billion in transaction experience. “We regularly see US, UK, and Asian PE firms competing with domestic trade buyers for the same assets — and that competitive tension is what creates the multiples we see in well-run sale processes.”

Domestic ASX-listed groups remain the most consistent buyers of mid-market healthcare assets, particularly in dental, diagnostics, and primary care. Their listed currency provides acquisition capacity and M&A is core to their growth strategy.

Offshore private equity — including US funds (KKR, Bain Capital, Warburg Pincus) and European healthcare-specialist funds — have been highly active in Australian healthcare for the same reasons they pursue healthcare assets in developed markets globally: defensive earnings, demographic tailwinds, and consolidation runway.

New Zealand and APAC acquirers increasingly look to Australia as the natural expansion market for their domestic healthcare networks, particularly in dental, veterinary, and allied health.

Family offices with healthcare mandates are consistent buyers of single-site practices and small regional networks, typically at below-PE pricing but with simpler transaction processes.

Regulatory Framework: What Sellers Must Know

Healthcare business sales in Australia involve regulatory considerations that do not arise in general commercial M&A:

AHPRA registration. The Australian Health Practitioner Regulation Agency governs registration for medical, dental, nursing, and allied health practitioners. Where the incoming owner is a practitioner, they must hold or obtain AHPRA registration in the relevant profession. Corporate ownership of healthcare practices is permitted, but each clinical role must be held by a registered practitioner.

Medicare provider numbers. Medicare provider numbers are personal to individual practitioners and do not transfer on a business sale. Buyers must apply for new provider numbers for each practising clinician, which can take 30–90 days and may cause billing disruption during transition. This is a key due diligence and transition planning issue in GP and specialist practice sales.

FIRB review. Foreign acquisitions of Australian healthcare businesses are subject to Foreign Investment Review Board approval where thresholds are met. FIRB review adds 30–90 days to the transaction timeline and is standard in sale agreements with offshore buyers.

Aged Care regulation. Sales of aged care facilities require notification to and approval from the Aged Care Quality and Safety Commission. The incoming operator must hold an approved provider status and meet all accreditation requirements.

Lyndon Advisory works with healthcare business owners across Australia to structure sale processes that account for these regulatory requirements — coordinating regulatory transition planning alongside the commercial M&A process to minimise disruption and protect transaction value.

Valuation and Sale Process Considerations

Beyond the sector multiples above, several factors determine where a specific healthcare business falls within the valuation range.

Key-person risk is the most common value discount in healthcare M&A. Where the owner-clinician generates 60% or more of revenue, buyers price in significant transition risk. Mitigation involves associate development, documented referral network relationships, and a structured handover period — often formalised through an earnout or extended employment arrangement.

Billing compliance is heavily scrutinised in Medicare-funded businesses. A quality of earnings review will examine Medicare billing records, referral patterns, bulk-billing ratios, and any Department of Health compliance history. Clean compliance records are a prerequisite for full valuation.

Lease and premises. Healthcare practices are often tied to specific premises with long-term leases. Buyers assess lease terms, rent-to-revenue ratios, and change of control provisions carefully. Favourable, long-term leases in high-catchment locations add meaningful value; unfavourable leases can materially impair it.

The optimal sale process for most Australian healthcare businesses is a structured confidential auction process with a curated buyer list — approaching 6–15 qualified buyers simultaneously to generate competitive tension. A well-run competitive process consistently achieves valuations 20–35% above indicative off-market offers.

---

Considering a sale of your Australian healthcare business? Lyndon Advisory provides specialist M&A advisory for healthcare business owners across Australia — GP clinics, dental groups, allied health practices, aged care facilities, and diagnostics businesses. Our 2% success fee, capped at US$300,000 with no retainer, is designed for mid-market healthcare transactions where traditional advisory fees would consume a disproportionate share of exit proceeds. Book a confidential valuation to understand what your practice could achieve in a structured sale process.